# Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma

> **NCT02645981** · PHASE2,PHASE3 · COMPLETED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 668 (actual)

## Conditions studied

- HCC

## Interventions

- **DRUG:** Donafenib
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02645981
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2019-11-27
- **Final completion:** 2019-12-17
- **Target enrollment:** 668 (ACTUAL)
- **Last updated:** 2020-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02645981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02645981, "Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02645981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*